Relationship between epoetin alfa dose and mortality: Findings from a marginal structural model

Clinical Journal of the American Society of Nephrology

Volumn 5, Issue 2, 2010, Pages 182-188

  Wang, Ouhong ^a   Kilpatrick, Ryan D ^a   Critchlow, Cathy W ^a   Ling, Xiang ^a   Bradbury, Brian D ^a   Gilbertson, David T ^b   Collins, Allan J ^b   Rothman, Kenneth J ^c,d   Acquavella, John F ^a  

^a AMGEN INC   (United States)

^b MINNEAPOLIS MEDICAL RESEARCH FOUNDATION   (United States)

^c RTI HEALTH SOLUTIONS   (United States)

^d BOSTON UNIVERSITY SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HEMOGLOBIN; RECOMBINANT ERYTHROPOIETIN;

ADULT; ANAMNESIS; ARTICLE; BODY WEIGHT; CONTROLLED STUDY; FEMALE; HEMODIALYSIS; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MORTALITY; RETROSPECTIVE STUDY;

ADULT; AGED; BIOLOGICAL MARKERS; CONFOUNDING FACTORS (EPIDEMIOLOGY); DOSE-RESPONSE RELATIONSHIP, DRUG; EPOETIN ALFA; FEMALE; HEMATINICS; HEMOGLOBINS; HUMANS; KIDNEY DISEASES; LOGISTIC MODELS; MALE; MIDDLE AGED; MODELS, STATISTICAL; RENAL DIALYSIS; RETROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME; UNITED STATES;

EID: 77749334761     PISSN: 15559041     EISSN: 1555905X     Source Type: Journal    
DOI: 10.2215/CJN.03040509     Document Type: Article

References (24)

1. Cotter DJ, Stefanik K, Zhang Y, Thamer M, Scharfstein D, Kaufman J: Hematocrit was not validated as a surrogate end point for survival among epoetin-treated hemodialysis patients. J Clin Epidemiol 57: 1086-1095, 2004
2. Zhang Y, Thamer M, Stefanik K, Kaufman J, Cotter DJ: Epoetin requirements predict mortality in hemodialysis patients. Am J Kidney Dis 44: 866-876, 2004
3. Bradbury BD, Wang O, Critchlow CW, Rothman KJ, Heagerty P, Keen M, Acquavella JF: Exploring relative mortality and epoetin alfa dose among hemodialysis patients. Am J Kidney Dis 51: 62-70, 2008
4. Roberts TL, Obrador GT, St Peter WL, Pereira BJ, Collins AJ: Relationship among catheter insertions, vascular access infections, and anemia management in hemodialysis patients. Kidney Int 66: 2429-2436, 2004
5. Teruel JL, Marcen R, Ocana J, Fernandez-Lucas M, Rivera M, Tabernero G, Ortuno J: Clinical significance of C-reactive protein in patients on hemodialysis: A longitudinal study. Nephron Clin Pract 100: c140-c145, 2005
6. Bodnar LM, Davidian M, Siega-Riz AM, Tsiatis AA: Marginal structural models for analyzing causal effects of timedependent treatments: an application in perinatal epidemiology. Am J Epidemiol 159: 926-934, 2004
7. Hernan MA, Brumback BA, Robins JM: Estimating the causal effect of zidovudine on CD4 count with a marginal structural model for repeated measures. Stat Med 21: 1689-1709, 2002
8. Regidor DL, Kopple JD, Kovesdy CP, Kilpatrick RD, McAllister CJ, Aronovitz J, Greenland S, Kalantar-Zadeh K: Associations between changes in hemoglobin and administered erythropoiesis-stimulating agent and survival in hemodialysis patients. J Am Soc Nephrol 17: 1181-1191, 2006
9. Volkova N, Arab L: Evidence-based systematic literature review of hemoglobin/hematocrit and all-cause mortality in dialysis patients. Am J Kidney Dis 47: 24-36, 2006
10. Hernan MA, Brumback B, Robins JM: Marginal structural models to estimate the causal effect of zidovudine on the survival of HIV-positive men. Epidemiology 11: 561-570, 2000
11. Robins JM, Hernan MA, Brumback B: Marginal structural models and causal inference in epidemiology. Epidemiology 11: 550-560, 2000
12. Robins JM. Correction for non-compliance in equivalence trials. Stat Med 17: 269-302; discussion 387-269, 1998
13. Cole SR, Hernan MA, Robins JM, Anastos K, Chmiel J, Detels R, Ervin C, Feldman J, Greenblatt R, Kingsley L, Lai S, Young M, Cohen M, Munoz A: Effect of highly active antiretroviral therapy on time to acquired immunodeficiency syndrome or death using marginal structural models. Am J Epidemiol 158: 687-694, 2003
14. Cole SR, Hernan MA: Constructing inverse probability weights for marginal structural models. Am J Epidemiol 168: 656-664, 2008
15. Efron B, Taibshirani R. Confidence intervals based on bottstrap percentiles. In: An Introduction to the Bootstrap, New York, Chapman & Hall, 1993, pp 168-177
16. Suissa S: Immortal time bias in pharmacoepidemiology. Am J Epidemiol 167: 492-499, 2008
17. Bradbury BD, Critchlow CW, Weir MR, Stewart R, Krishnan M, Hakim RH: Impact of elevated C-reactive protein levels on erythropoiesis-stimulating agent (ESA) dose and responsiveness in hemodialysis patients. Nephrol Dial Transplant 24: 919-925, 2009
18. Cook NR, Cole SR, Hennekens CH: Use of a marginal structural model to determine the effect of aspirin on cardiovascular mortality in the Physicians' Health Study. Am J Epidemiol 155: 1045-1053, 2002
19. Zhang Y, Thamer M, Cotter D, Kaufman J, Hernan M: Estimated effect of Epoetin dosage on survival among elderly hemodialysis patients in the United States. Clin J Am Soc Nephrol 4: 638-644, 2009
20. Mortimer KM, Neugebauer R, van der Laan M, Tager IB: An application of model-fitting procedures for marginal structural models. Am J Epidemiol 162: 382-388, 2005
21. Kalantar-Zadeh K, Lee GH, Miller JE, Streja E, Jing J, Robertson JA, Kovesdy CP: Predictors of hyporesponsiveness to erythropoiesis-stimulating agents in hemodialysis patients. Am J Kidney Dis 53: 823-834, 2009
22. Bradbury BD, Danese M, Gleeson M, Critchlow CW: Effect of Epoetin alfa (EPO) dose changes on hemoglobin and mortality among hemodialysis patients with hemoglobin levels persistently below 11 g/dL. Clin J Am Soc Nephrol 4: 630 - 637, 2009
23. Hernan MA, Robins JM: Estimating causal effects from epidemiological data. J Epidemiol Community Health 60: 578-586, 2006
24. Brunelli SM, Joffe MM, Israni RK, Yang W, Fishbane S, Berns JS, Feldman HI: History-adjusted marginal structural analysis of the association between hemoglobin variability and mortality among chronic hemodialysis patients. Clin J Am Soc Nephrol 3: 777-782, 200